人基因重组红细胞生成素皮下和静脉用药对尿毒症贫血的疗效比较

应用人基因重组红细胞生成素治疗１３８例尿毒症透析病人，随机分组比较ｓｃ和ｉｖ对贫血的疗效。起始剂量１００Ｕ·ｋｇ－１，ｔｉｗ，待血细胞比容（旧称红细胞压积）（ＨＣＴ）≥０．３０后减量，维持ＨＣＴ０．３０－０．３５。治疗２ｗｋＨＣＴ显著升高（Ｐ＜０．０１），２０ｗｋ内９６．４％病人ＨＣＴ≥０．３０。ｓｃ组治疗早期ＨＣＴ上升快、维持剂量低（均Ｐ＜０．０５）。表明本药治疗尿毒症贫血以ｓｃ更为有效和方便。

Comparison between subcutancous and intravenous injections on effects of recombinant human erythropoietin in uremic anemia

To compare the effects of recombinant human erythropoietin(rHuEPO)on uremic anemia between subcutaneous and intravenous administrations prospectively,138uremic patients(M 71,F 67;age 40±s 12a)with uncomplicated anemia were assigned randomly to receive rHuEPO by sc and iv.The initial dose was 100 U·kg-1,3 times per week. The target hematocrit(HCT)was 0.30-0.35.Before treatment, HCT of all patients was below 0.25(0.18±0.05).The results showed that HCT increased significantly 2 wk aftertreatment and increased to 0.30 or more in 96.4% of patients within 20 wk.In peritoneal dialysis sc and iv group, hemodialysis sc and iv groups, the increase rates of HCT(100-1·wk-1)in acute treatment phase were 1.54± 0.26 and 1.31± 0.28(P<0.01),0.98± 0.26 and 0.82±0.28( P<0.01),respectively;while the maintenance doses(U·kg-1·wk-1)were 171±49and 194±24(P<0.05),202± 36 and 231±52(P<0.01),respectively.No severe adverse effect was observed.It is concluded that rHuEPO is effective in correcting uremic anemia and sc is a more appropriate administration route than iv.